Salus IRB Competitors

As the drug development business of Laboratory Corporation of America Holdings (Labcorp) and the world’s most comprehensive drug development #CRO service company, we have helped pharmaceutical and biotech companies develop 100% of the top 50 prescription drugs in the marketplace today. Because of our broad experience and specialized expertise, we’re in a unique position to supply insights that go above and beyond testing. Together with our clients, we create solutions that transform potential into reality.

Advarra provides the platform, insights, and expertise that make clinical trials more efficient and connected. As the leading independent IRB, we bring more than 40 years of trusted oversight to the industry, setting the standard for ethical reviews while building the largest collection of digitized protocols and operational data. This combined intelligence guides the protocol’s entire journey—from design through review, activation, and conduct—fueling a smarter, more adaptive research ecosystem. Backed by decades of partnership with research sites, Advarra delivers the core systems and services that 50,000 investigators and their study teams depend on for optimal trial operations. Integrated with our solutions for study design, startup, and conduct, these capabilities create a collaborative technology platform trusted by sponsors and CROs globally. By designing AI-powered workflows that streamline operations, reduce administrative burden, and promote transparency for all study stakeholders, we’re reimagining what’s possible in clinical research.

Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines. With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. Our operations are strategically located in: Lincoln, Nebraska (Corporate Headquarters) Philadelphia, Pennsylvania Phoenix, Arizona Belfast, Northern Ireland,UK Zurich, Switzerland Vienna, Austria Richmond, Virginia Montreal, Quebec, Canada For more information, visit: www.celerion.com